CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Novo Nordisk was harshly criticized by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure to properly disclose payments to health and ...

Novo Nordisk’s Wegovy and Ozempic, which respectively target weight loss and diabetes, were added to the Medicare negotiation list this month, making it likely the company will have to cut ...

All hybrid closed-loop systems improved time in range and time ... allows a higher hypoglycemia threshold to be set for insulin delivery and further recommends calibrated preventive sugaring ...